The purpose of this study is to evaluate the efficacy and safety of Mitiglinide compared to Nateglinide for the treatment of type 2 diabetes.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
291
10mg tablet, 10mg TID
Hemoglobin A1C (HbA1C)
Time frame: -2, 0, 4, 8, 10, 12, 16, 20 week
Fasting plasma glucose level (FPG)
Time frame: 0, 4, 8, 12, 16, 20 week
Two-hour postprandial glucose level (PPG2)
Time frame: 0, 12, 20 week
One-hour postprandial glucose level (PPG1)
Time frame: 0, 12, 20 week
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.